FibroBiologics enters 5-year MSA with Charles River Labs for development and manufacturing services

FibroBiologics, Inc.

Master Services Agreement with Charles River Laboratories effective September 19, 2024.
Term expires September 19, 2029; services and fees set via future Statements of Work.
Covers development and CDMO services including cell/gene therapy products.
Either party can terminate on 90 days' notice; material breach cure period also 90 days.
Standard confidentiality, IP, warranty, and indemnity terms; financial caps redacted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.